CClinicalTrials.gg
CompletedNCT02541123VIGILANTUpdated Dec 16, 2020

Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma

An observational study in Traumatic Brain Injury, sponsored by Banyan Biomarkers, Inc. Completed at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-16.

Sponsored by Banyan Biomarkers, Inc · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
194
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale score 13-15 as well as in a group of uninjured control subjects.

02

Conditions studied

  • Traumatic Brain Injury

Keywords

  • Traumatic Brain Injury
  • Head Injury
03

In context

Brain Injuries

2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.

This study's enrollment of 194 is above the median of 100 across 690 observational studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Banyan Biomarkers, Inc is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects eligible for study participation will be over the age of 18 with a standard of care head CT result from the local neuroradiologist and be able to undergo an initial blood draw within 6 hours of head injury. Subjects who will be permitted into the study include those who will meet all the inclusion criteria and will have none of the exclusion criteria. Subjects enrolled into the control cohort will be recruited from the general population.

Eligibility criteria

Head Injured Cohorts Inclusion Criteria:

  • At least 18 years of age at screening.
  • Presented with a suspected traumatically induced head injury, as a result of insult to the head from an external force.
  • Workup includes head CT scan, as part of clinical emergency care and CT result (CT-positive or CT-negative for acute intracranial lesions) based on the local neuroradiologist's review is available to study staff.
  • CT scan and CT report used to determine eligibility must be available.
  • Glasgow Coma Scale score of 13-15 at the time of Informed Consent.
  • Weighs at least 110lbs (50kg), has not donated blood within the last 8 weeks, and is not anemic or has any other blood disorder which requires routine transfusions.
  • First study blood sample is able to be collected into a cohort that has not been closed to enrollment
  • Able to participate for up to 11 days following head injury.
  • Subject or legal representative is willing to undergo the Informed Consent process prior to enrollment into this study.
  • FOR CT NEGATIVE COHORTS ONLY: Subject must have experienced a Loss of Consciousness (LOC) \< 30 minutes, any Alteration of Consciousness (AOC), or any Post-traumatic amnesia (PTA) following the suspected head injury AND be expected to be admitted to the hospital, or remain in hospital for at least 24 hours in order to complete Visit 1 blood draws

Head Injured Cohorts Exclusion Criteria:

  • Participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study would be acceptable).
  • Time of injury cannot be determined.
  • Primary diagnosis of ischemic or hemorrhagic stroke.
  • Venipuncture not feasible
  • Neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
  • History of neurosurgery within the last 30 days.
  • Administration of blood transfusion after head injury and prior to the study blood draw.
  • Female who is pregnant or lactating.
  • Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation.

Control Cohort Inclusion Criteria

  • At least 18 years of age at screening
  • Weighs at least 110lbs (50kg), has not donated blood within the last 8 weeks, and is not anemic or has any other blood disorder which requires routine transfusions.
  • Healthy with no chronic or acute medical, neurologic, or psychiatric conditions (to the best of their knowledge).
  • Able to participate for up to 5 hours following the first study blood draw.
  • Willing to undergo the Informed Consent process prior to enrollment into this study.
  • Subject is able to be enrolled into a control cohort that has not yet been closed to enrollment

Control Cohort Exclusion Criteria

  • Participating in an interventional, therapeutic clinical study that may affect results of this study (an observational study would be acceptable).
  • Subject has sustained any significant bodily injury within the past week.
  • Venipuncture not feasible (i.e., skin integrity compromised at the venipuncture sites, blood vessel calcification (i.e., IV drug users, advanced atherosclerosis) both upper limbs missing (congenital or amputee)).
  • Neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
  • Female who is pregnant or lactating
  • History of neurosurgery within the last 30 days.
  • Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
194 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort A

    CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury

    Other: Blood draw

  • Cohort B

    CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury

    Other: Blood draw

  • Cohort C

    CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury

    Other: Blood draw

  • Cohort D

    CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury

    Other: Blood draw

  • Cohort E

    Uninjured control group

    Other: Blood draw

Interventions

  • OtherBlood draw

    Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.

06

What researchers measure

Primary outcomes

  1. Change in correlation of Banyan UCH-L1/GFAP Detection Assay result with acute intracranial lesions on head CT scan

    Time frame: initial, 4hr, 8hr,12hr,16hr, 20hr, 24hr, Day 7

07

Study locations

10 sites
  • University of Florida
    Gainesville, Florida 32608, United States
  • Orlando Regional Medical Center
    Orlando, Florida 32806, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Allegheny Singer Research Institute
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Klinikum rechts der Isar of the Technical University of Munich
    Munich, 81675, Germany
  • University of Pecs
    Pecs, 7632, Hungary
  • University of Szeged
    Szeged, 6725, Hungary
08

References and documents

Publications

  • Lewis LM, Papa L, Bazarian JJ, Weber A, Howard R, Welch RD. Biomarkers May Predict Unfavorable Neurological Outcome after Mild Traumatic Brain Injury. J Neurotrauma. 2020 Dec 15;37(24):2624-2631. doi: 10.1089/neu.2020.7071. Epub 2020 Sep 14. PubMed 32821007 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02541123
Lead sponsor
Banyan Biomarkers, Inc
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Sep 4, 2015
Start date
Jan 2016
Primary completion
Feb 28, 2017
Completion
Feb 28, 2017
Last update
Dec 16, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion